Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price shot up 5.4% during trading on Thursday . The company traded as high as $8.61 and last traded at $8.89. 60,465 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 926,053 shares. The stock had previously closed at $8.43.
Analyst Ratings Changes
A number of research firms have recently commented on REPL. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. HC Wainwright boosted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.43.
Check Out Our Latest Report on Replimune Group
Replimune Group Stock Performance
The stock has a market capitalization of $688.39 million, a price-to-earnings ratio of -2.91 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock's 50 day moving average is $8.39 and its two-hundred day moving average is $11.09.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.25) EPS. Analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.
Insider Transactions at Replimune Group
In other Replimune Group news, insider Konstantinos Xynos sold 7,952 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the transaction, the insider now directly owns 146,933 shares of the company's stock, valued at $1,184,279.98. This represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the transaction, the insider now owns 128,296 shares in the company, valued at approximately $1,032,782.80. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 in the last three months. Insiders own 8.80% of the company's stock.
Institutional Trading of Replimune Group
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of Replimune Group by 42.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company's stock worth $9,425,000 after acquiring an additional 232,822 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Replimune Group during the 4th quarter worth approximately $543,000. Nuveen Asset Management LLC boosted its position in shares of Replimune Group by 108.9% during the 4th quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company's stock worth $8,085,000 after acquiring an additional 347,993 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Replimune Group by 57.4% during the 4th quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after acquiring an additional 37,800 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.
About Replimune Group
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
